Synergistic interactions between two α2-adrenoceptor agonists, dexmedetomidine and ST-91, in two substrains of Sprague-Dawley rats

Pain

Volumn 85, Issue 1-2, 2000, Pages 135-143

  Graham, Brent A ^a   Hammond, Donna L ^a   Proudfit, Herbert K ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

2 Adrenoceptor; Antinociception; Dose response; Isobolographic analysis; Supra additive interaction; Synergy

Indexed keywords

2 (2,6 DIETHYLANILINO) 2 IMIDAZOLINE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DEXMEDETOMIDINE; IDAZOXAN; IMILOXAN; PRAZOSIN; YOHIMBINE;

ALPHA ADRENERGIC STIMULATION; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; MALE; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; STRAIN DIFFERENCE; TAIL FLICK TEST;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; CLONIDINE; DEXMEDETOMIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MALE; MOTOR ACTIVITY; PAIN MEASUREMENT; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, ADRENERGIC, ALPHA-2; SPECIES SPECIFICITY;

EID: 0033955367     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(99)00261-4     Document Type: Article

References (75)

1. Blaxall H.S., Murphy J.P., Baker J.C., Ray C., Bylund D.B. Characterization of the alpha-2C adrenergic receptor subtype in the opossum kidney and the OK cell line. J Pharmacol Exp Ther. 259:1991;323-329.
2. Bourgoin S., Pohl M., Mauborgne A., Benoliel J.J., Collin E., Hamon M., Cesselin F. Monoaminergic control of the release of calcitonin gene-related peptide- and substance P-like materials from rat spinal cord slices. Neuropharmacology. 32:1993;633-640.
3. Chapman V., Dickenson A.H. The effects of sandostatin and somatostatin on nociceptive transmission in the dorsal horn of the rat spinal cord. Neuropeptides. 23:1992;147-152.
4. Chrubasik J., Meynadier J., Blond S., Scherpereel P., Ackerman E., Weinstock M., Bonath K., Cramer H., Wunsch E. Somatostatin, a potent analgesic. Lancet. ii:1984;1208-1209.
5. Dalsgaard C., Hökfelt T., Johansson O., Elde R. Somatostatin immunoreactive cell bodies in the dorsal horn and the parasympathetic intermediolateral nucleus of the rat spinal cord. Neurosci Lett. 27:1981;335-339.
6. Duggan A.W., Weihe E. Central transmission of impulses in nociceptors: events in the superficial dorsal horn. Basbaum A.I., Besson J.-M. Towards a New Pharmacology of Pain. 1991;35-67 Wiley, New York.
7. Fisher B., Zornow M.H., Yaksh T.L., Peterson B.M. Antinociceptive properties of intrathecal dexmedetomidine in rats. Eur J Pharmacol. 192:1991;221-225.
8. Gaumann D.M., Yaksh T.L. Intrathecal somatostatin in rats: antinociceptive only in the presence of toxic effects. Anesthesiology. 68:1988;733-742.
9. Gaumann D.M., Grabow T.S., Yaksh T.L., Casey S.J., Rodriguez M. Intrathecal somatostatin, somatostatin analogs, substance P analog and dynorphin A cause comparable neurotoxicity in rats. Neuroscience. 39:1990;761-774.
10. Gebhart G.F. Modulatory effects of descending systems on spinal dorsal horn neurons. Yaksh T.L. Spinal Afferent Processing. 1986;391-416 Plenum, New York.
11. Go V.L.W., Yaksh T.L. Release of substance P from the cat spinal cord. J Physiol (Lond). 391:1987;141-167.
12. Graham B.A., Hammond D.L., Proudfit H.K. Differences in the antinociceptive effects of alpha2-adrenoceptor agonists in two substrains of Sprague-Dawley rats. J Pharmacol Exp Ther. 283:1997;511-519.
13. Graham B.A., Hammond D.L., Proudfit H.K. Intrathecal dexmedetomidine (DEX) and ST-91 act synergistically to produce antinociception in the rat. Soc Neurosci Abstr. 23:1997;1539.
14. Hammond D.L. Intrathecal administration: methodological considerations. Prog Brain Res. 77:1988;313-320.
15. 2-adrenergic receptors. Mol Pharmacol. 40:1991;407-412.
16. Howe J.R., Wang J.-Y., Yaksh T.L. Selective antagonism of the antinociceptive effect of intrathecally applied α-adrenergic agonists by intrathecal prazosin and intrathecal yohimbine. J Pharmacol Exp Ther. 224:1983;552-558.
17. 2 -adrenoceptor binding to, and the substance P, enkephalin, and neurotensin content of, the cat lumbar spinal cord. Neuroscience. 21:1987;385-394.
18. Hunter J.C., Fontana D.J., Hedley L.R., Jasper J.R., Lewis R., Link R.E., Secchi R., Sutton J., Eglen R.M. Assessment of the role of alpha2-adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br J Pharmacol. 122:1997;1339-1344.
19. Idänpään-Heikkilä J.J., Kalso E.A., Seppälä T. Antinociceptive actions of dexmedetomidine and the kappa-opioid agonist U-50,488H against noxious thermal, mechanical and inflammatory stimuli. J Pharmacol Exp Ther. 271:1994;1306-1313.
20. Johansson O., Hökfelt T., Elde R.P. Immunohistochemical distribution of somatostatin-like immunoreactivity in the central nervous system of the adult rat. Neuroscience. 13:1984;265-339.
21. Jones S.L. Descending noradrenergic influences on pain. Prog Brain Res. 88:1991;381-394.
22. Kalso E.A., Pöyghiä R., Rosenberg P.H. Spinal antinociception by dexmedetomidine, a highly selective alpha-2-adrenergic agonist. Pharmacol Toxicol. 68:1991;140-143.
23. Kamei J., Hitosugi H., Kasuya Y. Nociceptive responses to intrathecally administered substance P and somatostatin in diabetic mice. Life Sci. 52:1993;L31-PL36.
24. Kuraishi Y., Hirota N., Sato Y., Hino Y., Satoh M., Takagi H. Evidence that substance P and somatostatin transmit separate information related to pain in the spinal dorsal horn. Brain Res. 325:1985;294-298.
25. Kuraishi Y., Hirota N., Sato Y., Kaneko S., Satoh M., Takagi H. Noradrenergic inhibition of the release of substance P from the primary afferents in the rabbit spinal dorsal horn. Brain Res. 359:1985;177-182.
26. 2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic and anesthetic-sparing responses in vivo. Proc Natl Acad Sci USA. 94:1997;9950-9955.
27. Leah J., Menetrey D., de Pommery J. Neuropeptides in long ascending spinal tract cells in the rat: evidence for parallel processing of ascending information. Neuroscience. 24:1988;195-207.
28. Leff P., Dougall I.G., Harper D. Estimation of partial agonist affinity by interaction with a full agonist: a direct operational model-fitting approach. Br J Pharmacol. 110:1993;239-244.
29. Levine J.D., Fields H.L., Basbaum A.I. Peptides and the primary afferent nociceptor. J Neurosci. 13:1993;2273-2286.
30. Long J.B. Spinal subarachnoid injection of somatostatin causes neurological deficits and neuronal injury in rats. Eur J Pharmacol. 149:1988;287-296.
31. 2-adrenoceptor-subtype function. Trends Pharmacol Sci. 18:1997;211-219.
32. Marjamäki A., Luomala K., Ala-Uotila S., Scheinin M. Use of recombinant human alpha2-adrenoceptors to characterize subtype selectivity of antagonist binding. Eur J Pharmacol. 246:1993;219-226.
33. Marjamäki A., Pohjanoksa K., Ala-Uotila S., Sizmann D., Oker-Blom C., Kurose H., Scheinin M. Similar ligand binding in recombinant human alpha2C2-adrenoceptors produced in mammalian, insect and yeast cells. Eur J Pharmacol. 267:1994;117-121.
34. Mather C.S., Ho R.H. Golgi impregnated somatostatin immunoreactive neurons in lamina II of the rat spinal cord. Brain Res Bull. 28:1992;305-309.
35. McQuay H.J. Is there a place for alpha2 adrenergic agonists in the control of pain? Besson J.-M. Toward the Use of Noradrenergic Agonists for the Treatment of Pain. 1992;219-232 Elsevier, Amsterdam.
36. Mollenholt P., Post C., Rawal N., Freedman J., Hökfelt T., Paulsson I. Antinociceptive and 'neurotoxic' actions of somatostatin in rat spinal cord after intrathecal administration. Pain. 32:1988;95-105.
37. Mollenholt P., Post C., Paulsson I., Rawal N. Intrathecal and epidural somatostatin in rats: Can antinociception, motor effects and neurotoxicity be separated? Pain. 43:1990;363-370.
38. Monasky M.S., Zinsmeister A.R., Stevens C.W., Yaksh T.L. Interaction of intrathecal morphine and ST-91 on antinociception in the rat: dose-response analysis, antagonism and clearance. J Pharmacol Exp Ther. 254:1990;383-392.
39. Morton C.R., Hutchison W.D., Hendry I.A. Release of immunoreactive somatostatin in the spinal cord dorsal horn of the cat. Neuropeptides. 12:1989;189-197.
40. Morton C.R., Hutchison W.D., Hendry I.A., Duggan A.W. Somatostatin: Evidence for a role in thermal nociception. Brain Res. 488:1989;89-96.
41. Murase K., Nedeljkov V., Randic M. The actions of neuropeptides on dorsal horn neurons in the rat spinal cord slice preparation: an intracellular study. Brain Res. 234:1982;170-176.
42. Nagy J.I., Hunt S.P., Iversen L.L., Emson P.C. Biochemical and anatomical observations on the degeneration of peptide-containing primary afferent neurons after neonatal capsaicin. Neuroscience. 6:1981;1923-1934.
43. Nicholas A.P., Pieribone V., Hökfelt T. Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: an in situ hybridization study. J Comp Neurol. 328:1993;575-594.
44. Ohkubo T., Shibata M., Takahashi H., Inoki R. Roles of substance P and somatostatin on transmission of nociceptive information induced by formalin in spinal cord. J Pharmacol Exp Ther. 252:1990;1261-1268.
45. Ono H., Mishima A., Ono S., Fukuda H., Vasko M.R. Inhibitory effects of clonidine and tizanidine on release of substance P from slices of rat spinal cord and antagonism by alpha-adrenergic receptor antagonists. Neuropharmacology. 30:1991;585-589.
46. 3H]RX821002 binding to alpha-2 adrenergic receptor subtypes. J Pharmacol Exp Ther. 268:1994;1362-1367.
47. Pang I.-H., Vasko M.R. Morphine and norepinephrine but not 5-hydroxytryptamine and γ-aminobutyric acid inhibit the potassium-stimulated release of substance P from rat spinal cord slices. Brain Res. 376:1986;268-279.
48. Proudfit H.K. The behavioural pharmacology of the noradrenergic descending system. Besson J.-M. Toward the Use of Noradrenergic Agonists for the Treatment of Pain. 1992;119-136 Elsevier, Amsterdam.
49. Randic M., Miletic V. Depressant actions of methionine-enkephalin and somatostatin in cat dorsal horn neurones activated by noxious stimuli. Brain Res. 152:1978;196-202.
50. 3H]RX821002-labeled rat alpha2A-adrenergic receptors in cerebral cortex to human Halpha2A-adrenergic receptor and other populations of alpha-2 adrenergic subtypes. J Pharmacol Exp Ther. 270:1994;946-957.
51. Rivlin A.S., Tator C.H. Objective clinical assessment of motor function after experimental spinal cord injury in the rat. Neurosurgery. 47:1977;577-581.
52. 2A-adrenergic receptors in catecholaminergic and other brainstem neurons in the rat. Neuroscience. 56:1993;139-155.
53. Rosin D.L., Talley E.M., Lee A., Stornetta R.L., Gaylinn B.D., Guyenet P.G., Lynch K.R. Distribution of alpha2C-adrenergic receptor-like immunoreactivity in the rat central nervous system. J Comp Neurol. 372:1996;135-165.
54. Saeki S., Yaksh T.L. Suppression by spinal alpha-2 agonists of motor and autonomic responses evoked by low- and high-intensity thermal stimuli. J Pharmacol Exp Ther. 260:1992;795-802.
55. 2-adrenoceptor agonist. Mol Pharmacol. 51:1997;36-46.
56. Sandkühler J., Fu Q.G., Helmchen C. Spinal somatostatin superfusion in vivo affects activity of cat nociceptive dorsal horn neurons: Comparison with spinal morphine. Neuroscience. 34:1990;565-576.
57. Seybold V.S., Hylden J.L.K., Wilcox G.L. Intrathecal substance P and somatostatin in rats: behaviors indicative of sensation. Peptides. 3:1982;49-54.
58. Spampinato S., Romualdi P., Candeletti S., Cavicchini E., Ferri S. Distinguishable effects of intrathecal dynorphins, somatostatin, neurotensin and s-calcitonin on nociception and motor function in the rat. Pain. 35:1988;95-104.
59. 2-agonists and is necessary for spinal adrenergic/opioid synergy. J Neurosci. 17:1997;7157-7165.
60. 2C adrenergic receptor immunoreactivity in the rat spinal cord. J Neurosci. 18:1998;5928-5937.
61. 2C adrenoceptor subtypes - Radioligand binding and functional coupling to a cAMP-responsive reporter gene. Biochem Pharmacol. 51:1996;291-300.
62. Takano Y., Yaksh T.L. Characterization of the pharmacology of intrathecally administered alpha-2 agonists and antagonists in rats. J Pharmacol Exp Ther. 261:1992;764-772.
63. 2 adrenoceptor subtypes and intrinsic activity. J Pharmacol Exp Ther. 264:1993;327-335.
64. 2-adrenoceptor subtypes in the spinal cord. Eur J Pharmacol. 219:1992;465-468.
65. Takano M., Takano Y., Yaksh T.L. Release of calcitonin gene-related peptide (CGRP), substance P (SP), and vasoactive intestinal polypeptide (VIP) from rat spinal cord: modulation by alpha2 agonists. Peptides. 14:1993;371-378.
66. Tallarida R.J. Statistical analysis of drug combinations for synergism. Pain. 49:1992;93-97.
67. Tallarida R.J., Porreca F., Cowan R. Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sci. 45:1989;947-961.
68. Talley E.M., Rosin D.L., Lee A., Guyenet P.G., Lynch K.R. Distribution of alpha2A-adrenergic receptor-like immunoreactivity in the rat central nervous system. J Comp Neurol. 372:1996;111-134.
69. Tiseo P.J., Adler M.W., Liu-Chen L.Y. Differential release of substance P and somatostatin in the rat spinal cord in response to noxious cold and heat; effect of dynorphin A(1-17). J Pharmacol Exp Ther. 252:1990;539-545.
70. Wiesenfeld-Hallin Z. Intrathecal somatostatin modulates spinal sensory and reflex mechanisms: behavioural and electrophysiological studies in the rat. Neurosci Lett. 62:1985;69-74.
71. 2A messenger RNA expression. Neuroscience. 76:1997;241-260.
72. Yaksh T.L., Rudy T.A. Chronic catheterization of the spinal subarachnoid space. Physiol Behav. 17:1976;1031-1036.
73. Yasuoka S., Yaksh T.L. Effects on nociceptive threshold and blood pressure of intrathecally administered morphine and α-adrenergic agonists. Neuropharmacology. 22:1983;309-315.
74. Zar J.H. Biostatistical Analysis. 1974;Prentice-Hall, Englewood Cliffs, NJ.
75. Zeng D., Lynch K.R. Distribution of alpha2-adrenergic receptor mRNAs in the rat CNS. Mol Brain Res. 10:1991;219-225.